Phase I study of a combination of irinotecan and ifosfamide in advanced primary lung cancer

Kurume Medical Journal

Volumn 46, Issue 2, 1999, Pages 111-115

  Ichiki, Masao ^a   Rikimaru, Toru ^a   Okubo, Yo ^a   Gohara, Rumi ^a   Mitui, Takashi ^a   Kawayama, Tomotaka ^a   Kinoshita, Masaharu ^a   Oizumi, Kotaro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Ifosfamide; Irinotecan; Non small cell lung cancer; Small cell lung cancer

Indexed keywords

IFOSFAMIDE; IRINOTECAN;

ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTITIS; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NAUSEA; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SCHOOL CHILD; THROMBOCYTOPENIA; VOMITING;

EID: 0032875061     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.46.111     Document Type: Article

References (15)

1. Negoro S, Fukuoka M, Niitani H, Suzuki A, Taguchi T et al. A Phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 18:1013-1019. (in Japanese)
2. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225-1229.
3. Dejonge MA, and Verweij J. Moving the frontiers of cancer chemotherapy for solid tumors by changing the scope of drug development. Hematology 1992; 1:183-198.
4. Edelmen MJ, and Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1996; 37:385-393.
5. Goss GD, Dahrouge S, and Lochrin A. Recent advances in the treatment of non-small cell lung cancer. Anti-Cancer Drugs 1996; 7:363-385.
6. Drings P. Ifosfamide in the treatment of bronchial carcinoma. Contrib Oncol 1987; 26:294-318.
7. Drings P. European experience with ifosfamide in non-small-cell lung cancer. Semin Oncol 1989; 16 (suppl 3): 22-30.
8. Furuta T, and Yokoyama T. Combination therapy of CPT-11, a camptothecin derivative, with various anti-tumor drugs against L 1210 Leukemia. Jpn J Cancer Chemother 1991; 18:393-402. (in Japanese)
9. Kano Y, Suzuki K, Akutsu M, Suda K, Miura Y et al. Effects of CPT-11 in conbination with other anti-cancer agents in culture. Int J Cancer 1992; 50:604-610.
10. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, and Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21:71-74.
11. Negoro S, Fukuoka M, Masuda N, Takada M, Taguchi T et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83:1164-1168.
12. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K et al. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10:16-20.
13. Sasaki Y, Hakusui H, Mizuno S, Miya M, Saijo N et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995; 86:101-110.
14. Masters GA, Hoffman PC, Hsieh AL, Drinkard LC, Mick R et al. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:884-892.
15. Hoffman PC, Masters GA, Drinkard LC, Krauss SA, Smauels BL et al. Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: A Phase I study. Annals of Oncology 1996; 7:314-316.